What is it used for?
All products
Source of essential fatty acids (alpha-linolenic acid (ALA) and linoleic acid (LA)) for the maintenance of good health [Source note 2].
Source of omega-3 fatty acids for the maintenance of good health [Source note 3].
Source of alpha-linolenic acid (ALA) for the maintenance of good health [Source note 4].
Source of omega-6 fatty acids for the maintenance of good health [Source note 5].
Source of linoleic acid (LA) for the maintenance of good health [Source note 6].
Note: The above uses can be combined on the product label (e.g., Source of omega-3 and omega-6 fatty acids for the maintenance of good health).
What this guide covers
The solidus (/) indicates that the terms and/or statements are synonymous. Either term or statement may be selected by the applicant on the label.
Who does this guide cover?
As specified below.
How is it taken?
Oral
Which forms are covered?
this reference excludes foods or food-like dosage forms as indicated in the Compendium of references Guidance Document.
Acceptable Dosage Form(s)by Age Group
Children 2 years: The acceptable dosage forms are limited to emulsion/suspension and solution/liquid preparations (Giacoia et al. 2008; EMA/CHMP 2006).
Children 3-5 years: The acceptable dosage forms are limited to chewables, emulsion/suspension, powders and solution/liquid preparations (Giacoia et al. 2008; EMA/CHMP 2006).
Children 6-11 years, Adolescents 12-17 years, and Adults 18 years and older: The
Quantities
Method of preparation: Non-standardized fixed oil
| Uses or Purposes | Subpopulations¹,² | Subpopulations¹,² | Oil g/day / Min. | Oil g/day / Max. | Oil ml/day / Min. | Oil ml/day / Max. |
|---|---|---|---|---|---|---|
| Source of essential fatty acids, omega-3 fatty acids, and/or ALA | Children | 2-4 years | 0.04 | 5.33 | 0.17 | 5.67 |
| Source of essential fatty acids, omega-3 fatty acids, and/or ALA | Children | 5-9 years | 0.06 | 8 | 0.25 | 8.50 |
| Source of essential fatty acids, omega-3 fatty acids, and/or ALA | Children | 10-11 years | 0.12 | 16 | 0.5 | 17 |
| Source of essential fatty acids, omega-3 fatty acids, and/or ALA | Adolescents | 12-14 years | 0.12 | 16 | 0.5 | 17 |
| Source of essential fatty acids, omega-3 fatty acids, and/or ALA | Adolescents | 15-17 years | 0.23 | 32 | 1 | 34 |
| Source of essential fatty acids, omega-3 fatty acids, and/or ALA | Adults | 18 years and older | 0.23 | 32 | 1 | 34 |
| Source of omega-6 fatty acids and/or LA | Children | 2-4 years | 1.28 | 5.33 | 1.33 | 5.67 |
| Source of omega-6 fatty acids and/or LA | Children | 5-9 years | 1.93 | 8 | 2 | 8.50 |
| Source of omega-6 fatty acids and/or LA | Children | 10-11 years | 3.85 | 16 | 4 | 17 |
| Source of omega-6 fatty acids and/or LA | Adolescents | 12-14 years | 3.85 | 16 | 4 | 17 |
| Source of omega-6 fatty acids and/or LA | Adolescents | 15-17 years | 7.70 | 32 | 8 | 34 |
| Source of omega-6 fatty acids and/or LA | Adults | 18 years and older | 7.70 | 32 | 8 | 34 |
¹Children and adolescent doses were calculated as a proportion of the adult dose [Source note 7]. The use of Flaxseed oil in children and adolescents is supported by Bove 2001.
²Adult dose supported by the following references: IOM 2006; Schwab et al. 2006; Nordström et al. 1995; Kelley et al. 1993; Fischer et al. 1984.
Method of preparation: Standardized fixed oil
If potencies are declared, the only acceptable potencies are as follows:
35-65 % ALA [Source note 8]
11-24 % LA [Source note 9]
Note: The following potency information is considered as additional information and can be included on the label:
11-35% oleic acid [Source note 10]
XX% total omega-3 fatty acids
XX% total omega-6 fatty acids
How is it used?
The reference does not require an additional label statement in this section. This does not establish an absence of risk.
How long is it used?
The reference does not require an additional label statement in this section. This does not establish an absence of risk.
Warnings and precautions
The reference does not require an additional label statement in this section. This does not establish an absence of risk.
When should it be avoided?
The reference does not require an additional label statement in this section. This does not establish an absence of risk.
Possible side effects
The reference does not require an additional label statement in this section. This does not establish an absence of risk.
Storage
Must be established in accordance with the requirements described in the applicable product regulations.
All products, except those encapsulated
Refrigerate after opening [Source note 11].
All products (information for industry; not for labelling)
To be packaged in airtight container, protected from light [Source note 12].
Preparation details
Ingredient identity, preparation requirements, and other details that define the scope of this guide.
Ingredients and preparations
| Proper name(s) | Common name(s) | Source information / Source material(s) | Source information / Part(s) |
|---|---|---|---|
| Linum usitatissimum |
| Linum usitatissimum | Seed |
References: Proper name: USDA 2024; Common names: Brayfield and Cadart 2024, Ph. Eur. 2023, Hoffman 2003, Hendler and Rorvik 2001; Source information: Brayfield and Cadart 2024.
Other ingredients
Must be chosen from the current source ingredient database and must meet the limitations outlined in the database.
Preparation and quality requirements
The finished product specifications must be established in accordance with the requirements described in the source authority source’s product quality guidance.
The active ingredient must comply with the requirements outlined in the source ingredient database.
For products indicating one or more of the optional potencies listed in the dose section, an assay must be performed in order to confirm the potency(ies).
Guide change history
Updates to this SupplementSafety.org guide.
Minor updates
Updated guide wording, organization, and source presentation. Added our editorial change history.
Initial release
Initial SupplementSafety.org guide prepared from source reference material.
Validation: Not yet completed. Editorial updates do not constitute clinical validation.
Sources
Source information
This guide organizes source material about uses, preparations, amounts, and precautions. Read the conditions alongside each statement; the information may apply only to particular preparations or populations.
The source document includes supporting references. We have not independently summarized or assessed every cited study for this guide.
- Source document version
- April 25, 2025
- Source captured
- Aug 15, 2026
- Editorial work
- Editorial preparation. Independent clinical review has not been recorded for this guide.
Full citations are available through the link above. Verification is required to open them; reading this guide does not require verification.
Taking a medication too?
Explore our supplement–medication interaction checker. Its coverage and review status are shown with the results; a missing finding does not establish that a combination is safe.
